No Data
Kangmei Pharmaceutical (600518.SH) has seen no major changes in its fundamentals, and its profitability still needs further recovery.
Gelonghui November 11th | Kangmei Pharmaceutical (600518.SH) announced that on November 11, 2024, the company's stocks continued to hit the limit up, with a significant short-term increase in stock prices. In the first three quarters of 2024, the company achieved revenue of 3873.5583 million yuan, with a net income attributable to shareholders of the listed company of 5.0155 million yuan, and a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of -179.5222 million yuan. The company's production operation is currently normal, and the fundamentals have not undergone significant changes, with profitability still needing further recovery. The board of directors of the company confirmed, in addition to what has been publicly disclosed.
Kangmei Pharmaceutical's (SHSE:600518) Solid Earnings Are Supported By Other Strong Factors
Kangmei Pharmaceutical: Kangmei Pharmaceutical Third Quarter Report 2024
Kangmei Pharmaceutical Report for the Third Quarter of 2024
Kangmei Pharmaceutical (600518.SH): The net income for the first three quarters is 5,015,500 yuan.
On October 30th, Kangmei Pharmaceutical (600518.SH) released its third-quarter report, with a revenue of 3.87 billion yuan in the first three quarters, a year-on-year growth of 9.60%. The net income is 5.0155 million yuan, non-recurring net loss of 0.18 billion yuan, and basic earnings per share of 0.000 yuan.
Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?
No Data
No Data
